Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
NRx Pharmaceuticals, Inc. NRXP
$0.63
+$0 (0.16%)
На 18:01, 12 мая 2023
+217.46%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
45832643.00000000
-
week52high
1.68
-
week52low
0.49
-
Revenue
0
-
P/E TTM
-1
-
Beta
0.96782000
-
EPS
-0.67000000
-
Last Dividend
0.00000000
-
Next Earnings Date
11 мая 2023 г. в 20:00
Описание компании
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | 30 июн 2022 г. | |
| Ascendiant Capital | Buy | 09 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Willard Stephen H | A | 50000 | 50000 | 16 дек 2022 г. |
| VAN VOORHEES SETH | A | 46337 | 30000 | 16 дек 2022 г. |
| Javitt Jonathan C | D | 12899997 | 400000 | 07 дек 2022 г. |
| Javitt Daniel C. | D | 9634793 | 8441 | 30 ноя 2022 г. |
| Javitt Daniel C. | D | 9643234 | 13730 | 29 ноя 2022 г. |
| Flynn Patrick John | A | 1750 | 1750 | 28 ноя 2022 г. |
| Flynn Patrick John | A | 40209 | 2500 | 28 ноя 2022 г. |
| Flynn Patrick John | A | 37709 | 2500 | 28 ноя 2022 г. |
| VAN VOORHEES SETH | A | 16337 | 7021 | 25 ноя 2022 г. |
| VAN VOORHEES SETH | A | 9316 | 600 | 25 ноя 2022 г. |
Новостная лента
NRx Pharmaceuticals, Inc. (NRXP) Q4 2022 Earnings Call Transcript
Seeking Alpha
30 мар 2023 г. в 22:10
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Suzanne Messere - IR Stephen Willard - CEO Seth Van Voorhees - CFO Jonathan Javitt - Chief Scientist Conference Call Participants Jason Kolbert - Dawson James Vernon Bernadino - H.C. Wainwright Ed Woo - Ascendiant Capital Operator Good afternoon and welcome to the NRx Pharmaceuticals Full Year 2022 Results Conference Call.
NRx Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
PRNewsWire
17 мар 2023 г. в 06:47
RADNOR, Pa. , March 17, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage CNS biopharmaceutical company, a Delaware Corporation, today announced that it will release its fourth quarter and full year 2022 financial results after the market closes on Thursday, March 30, 2023, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/.
NRx Pharmaceuticals to Present Scientific Update at the 6th Annual Sachs Associates Neuroscience Innovation Forum in Conjunction with the 2023 J.P. Morgan Healthcare Conference
PRNewsWire
05 янв 2023 г. в 06:47
RADNOR, Pa. , Jan. 5, 2023 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will be presenting a scientific update of its Phase 2 and Phase 3 development program for NRX-101 in the treatment of suicidal bipolar depression at the upcoming 6th Annual Neuroscience Innovation Forum by Sachs Associates ("6th Annual NIF").
NRx Pharmaceuticals, Inc. (NRXP) Q3 2022 Earnings Call Transcript
Seeking Alpha
14 ноя 2022 г. в 09:52
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q3 2022 Earnings Conference Call November 14, 2022 8:00 AM ET Company Participants Suzanne Messere - Investor Relations Stephen Willard - Chief Executive Officer Seth Van Voorhees - Chief Financial Officer and Treasurer Jonathan Javitt - Founder and Chief Scientist Conference Call Participants Vernon Bernadino - H.C. Wainwright Ed Woo - Ascendiant Capital Operator Good morning, and welcome to the NRx Pharmaceuticals Third Quarter 2022 Earnings Conference Call.
5 Penny Stocks To Buy According To Analysts, Targets Up To 353%
PennyStocks
11 ноя 2022 г. в 10:38
Analysts say these are penny stocks to buy. Do you agree?